Post

New research · Ophthalmology
Frontiers in pharmacology · 2d
Case reportFrontiers in pharmacology · 2026

Case report: Vogt-Koyanagi-Harada-like uveitis induced by anti-PD-1 therapy (Sintilimab) in a gastric cancer patient: a case study.

Lei Wang, Ran Gao, Si-Yong Lin
Read paper
OphthalmologyCase report

Vision improved to 0.8 after stopping sintilimab and treating steroid-induced-like uveitis.

Case report: Vogt-Koyanagi-Harada-like uveitis induced by anti-PD-1 therapy (Sintilimab) in a gastric cancer patient: a case study.

Lei Wang … Si-Yong Lin
Frontiers in pharmacology · 2026
Background

Immune checkpoint inhibitors (immune checkpoint inhibitors), such as anti-programmed cell death-1 (PD-1) antibodies, have become pivotal in treating advanced cancers.

0.8
Results
0.8
vision recovered to near-normal reading level after treatment
More results

Sintilimab is a PD-1 inhibitor used in China, and this report describes a case of Vogt-Koyanagi-Harada-like uveitis following its long-term use for gastric cancer.

CASE PRESENTATION: A 55-year-old man presented with a 1-week history of bilateral blurred vision and tinnitus.

More results

His best-corrected visual acuity (BCVA) was 0.3 (approximately 6/20) in the right eye and 0.15 (approximately 6/40) in the left.

This case suggests that long-term therapy with sintilimab, a PD-1 antibody, can trigger Vogt-Koyanagi-Harada-like uveitis.

“
Conclusion · 1 of 3

This case suggests that long-term therapy with sintilimab, a PD-1 antibody, can trigger Vogt-Koyanagi-Harada-like uveitis.

Conclusion · 2 of 3

Early recognition, prompt discontinuation of the immune checkpoint inhibitors, and anti-inflammatory treatment are crucial for visual recovery.

Conclusion · 3 of 3

It highlights the necessity for ophthalmological monitoring in cancer patients on long-term immunotherapy, even after many months of treatment.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment